HealthTech startup Sequana Medical secures €24 million to fuel US launch of alfapump

Ghent-based Sequana Medical, a leader in dealing with liquid overload for liver illness, cardiac arrest, and cancer cells, has actually safeguarded EUR24 million in fresh funding, expanding its cash money path up until completion of 2025.

This financing bundle consists of a EUR4 million unprotected subordinated exchangeable finance from significant investors Companions in Equity and EQT, in addition to a EUR20 million share registration center with treasure International Return LLC SCS. The firm additionally has the choice to boost treasure’s dedication to EUR60 million, when the first quantity is attracted down.

CHIEF EXECUTIVE OFFICER Ian Crosbie shared his positive outlook regarding the funding and the upcoming industrial rollout: ” 2025 is a spots year for Sequana Medical with the United States industrial launch of the alfapump prepared for mid-Q3, complying with the FDA authorization of our PMA for this innovation gadget in December 2024. We are really happy with the solid responses we have actually gotten from United States hepatologists that aspire to use the alfapump to their people, and the possibility that it uses to essentially get rid of the requirement for restorative paracentesis and change their lifestyle.

“ With this funding bundle, we have the system to show the clear market chance for alfapump, and our capability to efficiently access this with our tiny specialized industrial group targeting United States liver transplant centres. We are pleased with the proceeded solid assistance from our essential investors and lending institutions, in addition to the brand-new equity dedication from treasure.”

Established In 2006, Sequana Medical has actually created the alfapump, an implantable pump system developed to get rid of the requirement for duplicated restorative paracentesis in liver illness people. Having actually safeguarded FDA authorization for its Pre-Market Authorization (PMA) application in December 2024, the firm is getting ready for its United States industrial launch in mid-Q3 2025, at first targeting 90 liver transplant centres.

The EUR4 million exchangeable finance will certainly be supplied by Companions in Equity and EQT, with the possibility for added lending institutions from a previous funding round to surrender their financial investments right into the brand-new finance. The terms enable conversion right into firm shares at a 25% price cut to the volume-weighted typical trading rate, supplying versatility for capitalists while making sure the firm preserves liquidity throughout its essential United States growth.

At The Same Time, the EUR20 million share registration center with treasure allows Sequana Medical to provide shares over a three-year duration, with an alternative to expand this dedication as much as EUR60 million. TREASURE, a Luxembourg-based alternate financial investment team with workplaces in Paris, New York City, and the Bahamas, has actually structured the arrangement to offer financing as needed, enabling the firm to handle its economic technique abreast with industrial turning points.

Furthermore, Sequana Medical has actually renegotiated its existing financial obligation contracts, safeguarding enhanced payment terms for lendings from Kreos Funding and PMV Standaardleningen NV, additionally reinforcing its economic setting.

With United States commercialisation coming up, Sequana Medical is placing itself for a critical year. The alfapump system, which has actually currently been assigned an Innovation Gadget by the FDA, has supposedly currently showed its capability to substantially enhance person lifestyle by lowering the requirement for duplicated health center brows through.

The firm prepares to introduce with a little, specialized sales pressure, targeting high-value liver transplant centres that manage most of instances.

By safeguarding this funding, Sequana Medical intends to perform its United States market technique successfully, while proceeding growth of its Straight Salt Elimination (DSR) treatment, which has actually revealed appealing cause resolving liquid overload in cardiac arrest people.

The article HealthTech startup Sequana Medical secures €24 million to fuel US launch of alfapump showed up initially on EU-Startups.